Jacqueline Ann Langdon MacArthur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacqueline Ann Langdon MacArthur has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
- Helen Parkinson
EMBL-EBI
9 shared publications - Aoife McMahon
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK
6 shared publications - Fiona Cunningham
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
6 shared publications - Joannella Morales
European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge, UK
5 shared publications - Michael Inouye
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
5 shared publications - Paul Flicek
European Molecular Biology Laboratory, European Bioinformatics Institute
5 shared publications
Latest Publications
- Open Access
OPEN: A Community-Informed Metadata Framework for Interoperable Computable Phenotypes
Objective: To identify community-prioritized metadata for reporting and sharing computable phenotypes (CPs), develop a cross-library candidate framework, assess alignment between user requirements and library metadata, and test the feasibility of metadata exchange. Materials and Methods: We combined an international, library-led effort by the Open PhEnomics Network (OPEN) consortium with a UK community consensus-building exercise aimed at improving the FAIRness (Findable, Accessible, Interoperable, Reusable) of CPs. The consortium performed a cross-library field comparison and literature review to inform candidate fields, refined through consortium consensus. The community approach was developed through stakeholder interviews, a survey, and workshop, guided by a working group. Community requirements were interpretively mapped to the resulting framework and classified into conformance tiers. Interoperability was tested by manually and programmatically mapping diabetes-related phenotypes across libraries. Results: The library-led process produced 23 candidate fields spanning phenotype description, data/technical details, and performance domains. Thirteen fields aligned across all five libraries, and 22 fields aligned with published CP library desiderata. Interoperability testing successfully catalogued phenotypes through manual mapping, with API-mediated mapping achieving 63–76% metadata field completeness across libraries. A community survey (n=124 respondents) identified six metadata elements with majority support as mandatory: description, coding terminology, phenotype type, version history, unique identifier, and data source. Logic representation and validation requirements were rated as mostly context-dependent. Community-identified priorities showed strong alignment with the OPEN framework, though some requirements were only partially represented. Discussion: Through a consensus-based, community-driven approach, we established a CP framework enabling interoperability across libraries. Conclusion: OPEN provides a credible, community-informed foundation for a FAIR CP metadata standard.
Open AccessOPEN: A Community-Informed Metadata Framework for Interoperable Computable Phenotypes
Objective: To identify community-prioritized metadata for reporting and sharing computable phenotypes (CPs), develop a cross-library candidate framework, assess alignment between user requirements and library metadata, and test the feasibility of metadata exchange. Materials and Methods: We combined an international, library-led effort by the Open PhEnomics Network (OPEN) consortium with a UK community consensus-building exercise aimed at improving the FAIRness (Findable, Accessible, Interoperable, Reusable) of CPs. The consortium performed a cross-library field comparison and literature review to inform candidate fields, refined through consortium consensus. The community approach was developed through stakeholder interviews, a survey, and workshop, guided by a working group. Community requirements were interpretively mapped to the resulting framework and classified into conformance tiers. Interoperability was tested by manually and programmatically mapping diabetes-related phenotypes across libraries. Results: The library-led process produced 23 candidate fields spanning phenotype description, data/technical details, and performance domains. Thirteen fields aligned across all five libraries, and 22 fields aligned with published CP library desiderata. Interoperability testing successfully catalogued phenotypes through manual mapping, with API-mediated mapping achieving 63–76% metadata field completeness across libraries. A community survey (n=124 respondents) identified six metadata elements with majority support as mandatory: description, coding terminology, phenotype type, version history, unique identifier, and data source. Logic representation and validation requirements were rated as mostly context-dependent. Community-identified priorities showed strong alignment with the OPEN framework, though some requirements were only partially represented. Discussion: Through a consensus-based, community-driven approach, we established a CP framework enabling interoperability across libraries. Conclusion: OPEN provides a credible, community-informed foundation for a FAIR CP metadata standard.
- Open Access
Measurement of quality of stroke care with national electronic health records: a prospective cohort study during and after the COVID-19 pandemic
Objectives: To evaluate the value of linked electronic health records (EHRs) for measuring stroke care quality in England before and after the COVID-19 pandemic, focusing on metrics not routinely captured: stroke incidence, dispensing of secondary prevention medications and a proxy of disability—time spent at home after stroke (‘home-time’). Design: Prospective cohort study using national linked datasets. Setting: England-wide health data linkage including the Sentinel Stroke National Audit Programme (SSNAP), primary and secondary care, dispensed medications and mortality records, accessed via National Health Service (NHS) England’s Secure Data Environment. Participants: 425 675 adults with a first stroke between 1 January 2020 and 31 December 2023; data were available for 304 210 in primary care, 279 825 in hospital admissions, 220 470 in SSNAP and 59 465 in death records. Main outcome measures: Annual stroke incidence; first-year medication dispensing rates for antiplatelets, anticoagulants, antihypertensives and lipid-lowering agents (with a 1-month washout period) and home-time at 180 days post stroke. Results: Stroke ascertainment was highest when combining all sources, with 10.8% of non-fatal ischaemic strokes recorded exclusively in primary care and 19.4% of fatal strokes identified solely through death records. Standardised annual stroke incidence rose from 227.6 (95% CI 226.1 to 229.0) to 244.8 (95% CI 243.4 to 246.3) per 100 000 over the study period including the COVID-19 pandemic. During the COVID-19 lockdown, non-fatal stroke recordings decreased while stroke-related deaths rose, indicating that recording quality was sensitive to shifts in healthcare-seeking behaviour during the pandemic. Among people with ischaemic stroke, 89.1% received an antiplatelet or anticoagulant, 44.5% an antihypertensive and 80.5% a lipid-lowering therapy. For haemorrhagic stroke, these proportions were: for anticoagulants 13.5%, antiplatelets 13.2%, antihypertensives 46.6% and lipid lowering 41.1%. Medication dispensing for stroke prevention declined with increasing age and comorbidity, but varied little by ethnicity, region or pandemic period. Mean home-time within 180 days of stroke was 166.6 (95% CI 166.4 to 166) days, decreasing with greater age (141.4 days for 90 years or older (95% CI 140.7 to 142.1)), deprivation (166.4 days (95% CI 166.1 to 166.6) for most deprived quintile) and stroke severity (137.4 days for National Institutes of Health Stroke Scale (NIHSS) score on arrival over 22 (95% CI 135.8 to 139.1)) and increasing with years from the COVID-19 pandemic 2023 (169.3 days (95% CI 169.0 to 169.5) vs 2020 164.4 days (95% CI 164.1 to 164.7)). Conclusions: Standardised stroke incidence increased significantly over the study period, highlighting a growing public health burden that persisted despite disruptions due to the pandemic although variation in case ascertainment and stroke coding practices was observed. While secondary prevention coverage for antiplatelets and lipids was high, lower rates of dispensing of antihypertensives, particularly in older and comorbid populations, potentially signal a target for improvement. Home-time represents a sensitive, person-centred outcome that exposes disparities linked to socioeconomic deprivation and clinical severity that can be used to enhance routine stroke audits. These findings justify the expansion of linked EHR infrastructure and the modernisation of governance frameworks to enable the longitudinal evaluation of care quality beyond the COVID-19 era.
Open AccessMeasurement of quality of stroke care with national electronic health records: a prospective cohort study during and after the COVID-19 pandemic
Objectives: To evaluate the value of linked electronic health records (EHRs) for measuring stroke care quality in England before and after the COVID-19 pandemic, focusing on metrics not routinely captured: stroke incidence, dispensing of secondary prevention medications and a proxy of disability—time spent at home after stroke (‘home-time’). Design: Prospective cohort study using national linked datasets. Setting: England-wide health data linkage including the Sentinel Stroke National Audit Programme (SSNAP), primary and secondary care, dispensed medications and mortality records, accessed via National Health Service (NHS) England’s Secure Data Environment. Participants: 425 675 adults with a first stroke between 1 January 2020 and 31 December 2023; data were available for 304 210 in primary care, 279 825 in hospital admissions, 220 470 in SSNAP and 59 465 in death records. Main outcome measures: Annual stroke incidence; first-year medication dispensing rates for antiplatelets, anticoagulants, antihypertensives and lipid-lowering agents (with a 1-month washout period) and home-time at 180 days post stroke. Results: Stroke ascertainment was highest when combining all sources, with 10.8% of non-fatal ischaemic strokes recorded exclusively in primary care and 19.4% of fatal strokes identified solely through death records. Standardised annual stroke incidence rose from 227.6 (95% CI 226.1 to 229.0) to 244.8 (95% CI 243.4 to 246.3) per 100 000 over the study period including the COVID-19 pandemic. During the COVID-19 lockdown, non-fatal stroke recordings decreased while stroke-related deaths rose, indicating that recording quality was sensitive to shifts in healthcare-seeking behaviour during the pandemic. Among people with ischaemic stroke, 89.1% received an antiplatelet or anticoagulant, 44.5% an antihypertensive and 80.5% a lipid-lowering therapy. For haemorrhagic stroke, these proportions were: for anticoagulants 13.5%, antiplatelets 13.2%, antihypertensives 46.6% and lipid lowering 41.1%. Medication dispensing for stroke prevention declined with increasing age and comorbidity, but varied little by ethnicity, region or pandemic period. Mean home-time within 180 days of stroke was 166.6 (95% CI 166.4 to 166) days, decreasing with greater age (141.4 days for 90 years or older (95% CI 140.7 to 142.1)), deprivation (166.4 days (95% CI 166.1 to 166.6) for most deprived quintile) and stroke severity (137.4 days for National Institutes of Health Stroke Scale (NIHSS) score on arrival over 22 (95% CI 135.8 to 139.1)) and increasing with years from the COVID-19 pandemic 2023 (169.3 days (95% CI 169.0 to 169.5) vs 2020 164.4 days (95% CI 164.1 to 164.7)). Conclusions: Standardised stroke incidence increased significantly over the study period, highlighting a growing public health burden that persisted despite disruptions due to the pandemic although variation in case ascertainment and stroke coding practices was observed. While secondary prevention coverage for antiplatelets and lipids was high, lower rates of dispensing of antihypertensives, particularly in older and comorbid populations, potentially signal a target for improvement. Home-time represents a sensitive, person-centred outcome that exposes disparities linked to socioeconomic deprivation and clinical severity that can be used to enhance routine stroke audits. These findings justify the expansion of linked EHR infrastructure and the modernisation of governance frameworks to enable the longitudinal evaluation of care quality beyond the COVID-19 era.
- Open Access
Delphi approach to prioritising research in cardiovascular and kidney disease using routinely collected data
Objectives Chronic kidney disease (CKD) and cardiovascular disease (CVD) are leading global causes of morbidity and mortality, often coexisting and sharing common risk factors. Despite their interconnection, clinical care and research for affected individuals remain siloed and fragmented. Recognising the need for integrated approaches, this study aimed to identify and prioritise key research questions at the intersection of CKD and CVD that can be addressed using real-world healthcare data to inform more cohesive and data-driven strategies for improving outcomes across both disease areas. Design, setting and participants A three-round modified Delphi process was conducted: Round 1 online survey collected open-ended research questions about CKD-CVD priorities via BHF Data Science Centre, Kidney Research UK, UK Renal Health Data Network and HDR UK public involvement channels; Round 2 in-person workshop refined and consolidated items; Round 3 online survey prioritised items across urgency, feasibility and impact using 5-point scales. Main outcome measures Survey mean scores for each research question were calculated across the three prioritisation domains, each scored out of 5. The top-ranked questions were identified based on overall scores. Results Six thematic domains emerged: risk prediction and early detection, treatment optimisation, health inequities, multimorbidity, disease mechanisms and data infrastructure. The highest-rated research priority was “What are the most effective strategies for prevention, early diagnosis and intervention in CKD?” with a mean score of 12.6 (SD 1.1). Other top priorities included evaluating the cost-effectiveness of early treatment, identifying predictors of kidney failure and assessing the benefits of treating cardiovascular and renal conditions independently. Conclusions Across domains, prevention/early detection and early treatment in CKD consistently ranked highest, indicating near-term opportunities for data-enabled cardio-renal research and service improvement; these priorities can inform funder calls, data linkage work and evaluation studies.
Open AccessDelphi approach to prioritising research in cardiovascular and kidney disease using routinely collected data
Objectives Chronic kidney disease (CKD) and cardiovascular disease (CVD) are leading global causes of morbidity and mortality, often coexisting and sharing common risk factors. Despite their interconnection, clinical care and research for affected individuals remain siloed and fragmented. Recognising the need for integrated approaches, this study aimed to identify and prioritise key research questions at the intersection of CKD and CVD that can be addressed using real-world healthcare data to inform more cohesive and data-driven strategies for improving outcomes across both disease areas. Design, setting and participants A three-round modified Delphi process was conducted: Round 1 online survey collected open-ended research questions about CKD-CVD priorities via BHF Data Science Centre, Kidney Research UK, UK Renal Health Data Network and HDR UK public involvement channels; Round 2 in-person workshop refined and consolidated items; Round 3 online survey prioritised items across urgency, feasibility and impact using 5-point scales. Main outcome measures Survey mean scores for each research question were calculated across the three prioritisation domains, each scored out of 5. The top-ranked questions were identified based on overall scores. Results Six thematic domains emerged: risk prediction and early detection, treatment optimisation, health inequities, multimorbidity, disease mechanisms and data infrastructure. The highest-rated research priority was “What are the most effective strategies for prevention, early diagnosis and intervention in CKD?” with a mean score of 12.6 (SD 1.1). Other top priorities included evaluating the cost-effectiveness of early treatment, identifying predictors of kidney failure and assessing the benefits of treating cardiovascular and renal conditions independently. Conclusions Across domains, prevention/early detection and early treatment in CKD consistently ranked highest, indicating near-term opportunities for data-enabled cardio-renal research and service improvement; these priorities can inform funder calls, data linkage work and evaluation studies.
- Open Access
Measurement of quality of stroke care with national electronic health records: a prospective cohort study during and after the COVID-19 pandemic
Objectives: To evaluate the value of linked electronic health records (EHRs) for measuring stroke care quality in England before and after the COVID-19 pandemic, focusing on metrics not routinely captured: stroke incidence, dispensing of secondary prevention medications, and a proxy of disability—time spent at home after stroke (“home-time”). Design: Prospective cohort study using national linked datasets. Setting: England-wide health data linkage including the Sentinel Stroke National Audit Programme (SSNAP), primary and secondary care, dispensed medications, and mortality records, accessed via NHS England’s Secure Data Environment. Participants: 425,675 adults with a first stroke between 1 January 2020 and 31 December 2023; data were available for 304,210 in primary care, 279,825 in hospital admissions, 220,470 in SSNAP, and 59,465 in death records. Main outcome measures: Annual stroke incidence; first-year medication dispensing rates for antiplatelets, anticoagulants, antihypertensives, and lipid-lowering agents; and home-time at 180 days post-stroke. Results: Stroke ascertainment was highest when combining all sources, with 10.8% of non-fatal ischaemic strokes recorded exclusively in primary care and 19.4% of fatal strokes identified solely through death records. Standardised annual stroke incidence rose from 227.6 [95% CI 226.1, 229.0] to 244.8 [95% CI 243.4, 246.3] per 100,000 over the study period including the COVID-19 pandemic. During the COVID-19 lockdown, non-fatal stroke recordings decreased while stroke-related deaths rose, indicating that recording quality was sensitive to shifts in healthcare-seeking behavior during the pandemic. Among people with ischaemic stroke, 89.1% received an antiplatelet or anticoagulant, 44.5% an antihypertensive, and 80.5% a lipid-lowering therapy. For haemorrhagic stroke, these proportions were, for anticoagulants 13.5%, antiplatelets 13.2%, antihypertensives 46.6%, and lipid lowering 41.1%. Medication dispensing for stroke prevention declined with increasing age and comorbidity but varied little by ethnicity, region, or pandemic period. Mean home-time within 180 days of stroke was 166.6 [95% CI 166.4, 166] days, decreasing with greater age (141.4 days for 90 years or older [95% CI 140.7, 142.1]), deprivation (166.4 [95% CI 166.1, 166.6] for most deprived quintile), and stroke severity (137.4 days for NIHSS score on arrival over 22 [95% CI 135.8, 139.1]), and increasing with years from the COVID-19 pandemic 2023 169.3 days [95% CI 169.0, 169.5] vs. 2020 164.4 days [95% CI 164.4 [164.1, 164.7]). Conclusions: Standardised stroke incidence increased significantly over the study period, highlighting a growing public health burden that persisted despite disruptions due to the pandemic. While secondary prevention coverage for antiplatelets and lipids was high, the suboptimal dispensing of antihypertensives, particularly in older and comorbid populations, signals a critical target for clinical optimisation. Home-time represents a sensitive, person-centered outcome that exposes disparities linked to socioeconomic deprivation and clinical severity that can be used to enhance routine stroke audits. These findings justify the expansion of linked EHR infrastructure and the modernisation of governance frameworks to enable the longitudinal evaluation of care quality beyond the COVID-19 era. Strengths and Limitations of this Study: This study utilises a whole-population linkage of national audit (SSNAP), primary care (GDPPR), hospital (HES), and mortality (ONS) records, which maximises case ascertainment compared to routine audits. The use of NHS Business Services Authority (NHSBSA) medication dispensing data potentially provides a more accurate proxy for medication adherence than primary care prescribing records alone. The inclusion of primary care records enables capture of patients not admitted to hospital or managed in ambulatory settings, while linkage with hospital records allows longitudinal measurement of ‘home-time’ following stroke. Potential misclassification of stroke subtypes and first-ever versus recurrent stroke events remains a risk due to the varying PPV of ICD-10 and SNOMED-CT concepts in electronic health records from different healthcare settings. The analysis is unable to account for medications prescribed in the private sector or clinical factors not captured in routine electronic health records, such as specific reasons for contraindications, prior tolerance, or eligibility to secondary prevention.
Open AccessMeasurement of quality of stroke care with national electronic health records: a prospective cohort study during and after the COVID-19 pandemic
Objectives: To evaluate the value of linked electronic health records (EHRs) for measuring stroke care quality in England before and after the COVID-19 pandemic, focusing on metrics not routinely captured: stroke incidence, dispensing of secondary prevention medications, and a proxy of disability—time spent at home after stroke (“home-time”). Design: Prospective cohort study using national linked datasets. Setting: England-wide health data linkage including the Sentinel Stroke National Audit Programme (SSNAP), primary and secondary care, dispensed medications, and mortality records, accessed via NHS England’s Secure Data Environment. Participants: 425,675 adults with a first stroke between 1 January 2020 and 31 December 2023; data were available for 304,210 in primary care, 279,825 in hospital admissions, 220,470 in SSNAP, and 59,465 in death records. Main outcome measures: Annual stroke incidence; first-year medication dispensing rates for antiplatelets, anticoagulants, antihypertensives, and lipid-lowering agents; and home-time at 180 days post-stroke. Results: Stroke ascertainment was highest when combining all sources, with 10.8% of non-fatal ischaemic strokes recorded exclusively in primary care and 19.4% of fatal strokes identified solely through death records. Standardised annual stroke incidence rose from 227.6 [95% CI 226.1, 229.0] to 244.8 [95% CI 243.4, 246.3] per 100,000 over the study period including the COVID-19 pandemic. During the COVID-19 lockdown, non-fatal stroke recordings decreased while stroke-related deaths rose, indicating that recording quality was sensitive to shifts in healthcare-seeking behavior during the pandemic. Among people with ischaemic stroke, 89.1% received an antiplatelet or anticoagulant, 44.5% an antihypertensive, and 80.5% a lipid-lowering therapy. For haemorrhagic stroke, these proportions were, for anticoagulants 13.5%, antiplatelets 13.2%, antihypertensives 46.6%, and lipid lowering 41.1%. Medication dispensing for stroke prevention declined with increasing age and comorbidity but varied little by ethnicity, region, or pandemic period. Mean home-time within 180 days of stroke was 166.6 [95% CI 166.4, 166] days, decreasing with greater age (141.4 days for 90 years or older [95% CI 140.7, 142.1]), deprivation (166.4 [95% CI 166.1, 166.6] for most deprived quintile), and stroke severity (137.4 days for NIHSS score on arrival over 22 [95% CI 135.8, 139.1]), and increasing with years from the COVID-19 pandemic 2023 169.3 days [95% CI 169.0, 169.5] vs. 2020 164.4 days [95% CI 164.4 [164.1, 164.7]). Conclusions: Standardised stroke incidence increased significantly over the study period, highlighting a growing public health burden that persisted despite disruptions due to the pandemic. While secondary prevention coverage for antiplatelets and lipids was high, the suboptimal dispensing of antihypertensives, particularly in older and comorbid populations, signals a critical target for clinical optimisation. Home-time represents a sensitive, person-centered outcome that exposes disparities linked to socioeconomic deprivation and clinical severity that can be used to enhance routine stroke audits. These findings justify the expansion of linked EHR infrastructure and the modernisation of governance frameworks to enable the longitudinal evaluation of care quality beyond the COVID-19 era. Strengths and Limitations of this Study: This study utilises a whole-population linkage of national audit (SSNAP), primary care (GDPPR), hospital (HES), and mortality (ONS) records, which maximises case ascertainment compared to routine audits. The use of NHS Business Services Authority (NHSBSA) medication dispensing data potentially provides a more accurate proxy for medication adherence than primary care prescribing records alone. The inclusion of primary care records enables capture of patients not admitted to hospital or managed in ambulatory settings, while linkage with hospital records allows longitudinal measurement of ‘home-time’ following stroke. Potential misclassification of stroke subtypes and first-ever versus recurrent stroke events remains a risk due to the varying PPV of ICD-10 and SNOMED-CT concepts in electronic health records from different healthcare settings. The analysis is unable to account for medications prescribed in the private sector or clinical factors not captured in routine electronic health records, such as specific reasons for contraindications, prior tolerance, or eligibility to secondary prevention.
- Open Access
- 7 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e42449
Charting a Course for Smartphones and Wearables to Transform Population Health Research
The use of data from smartphones and wearable devices has huge potential for population health research, given the high level of device ownership; the range of novel health-relevant data types available from consumer devices; and the frequency and duration with which data are, or could be, collected. Yet, the uptake and success of large-scale mobile health research in the last decade have not met this intensely promoted opportunity. We make the argument that digital person-generated health data are required and necessary to answer many top priority research questions, using illustrative examples taken from the James Lind Alliance Priority Setting Partnerships. We then summarize the findings from 2 UK initiatives that considered the challenges and possible solutions for what needs to be done and how such solutions can be implemented to realize the future opportunities of digital person-generated health data for clinically important population health research. Examples of important areas that must be addressed to advance the field include digital inequality and possible selection bias; easy access for researchers to the appropriate data collection tools, including how best to harmonize data items; analysis methodologies for time series data; patient and public involvement and engagement methods for optimizing recruitment, retention, and public trust; and methods for providing research participants with greater control over their data. There is also a major opportunity, provided through the linkage of digital person-generated health data to routinely collected data, to support novel population health research, bringing together clinician-reported and patient-reported measures. We recognize that well-conducted studies need a wide range of diverse challenges to be skillfully addressed in unison (eg, challenges regarding epidemiology, data science and biostatistics, psychometrics, behavioral and social science, software engineering, user interface design, information governance, data management, and patient and public involvement and engagement). Consequently, progress would be accelerated by the establishment of a new interdisciplinary community where all relevant and necessary skills are brought together to allow for excellence throughout the life cycle of a research study. This will require a partnership of diverse people, methods, and technologies. If done right, the synergy of such a partnership has the potential to transform many millions of people’s lives for the better.
- 7 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e42449
Open AccessCharting a Course for Smartphones and Wearables to Transform Population Health Research
The use of data from smartphones and wearable devices has huge potential for population health research, given the high level of device ownership; the range of novel health-relevant data types available from consumer devices; and the frequency and duration with which data are, or could be, collected. Yet, the uptake and success of large-scale mobile health research in the last decade have not met this intensely promoted opportunity. We make the argument that digital person-generated health data are required and necessary to answer many top priority research questions, using illustrative examples taken from the James Lind Alliance Priority Setting Partnerships. We then summarize the findings from 2 UK initiatives that considered the challenges and possible solutions for what needs to be done and how such solutions can be implemented to realize the future opportunities of digital person-generated health data for clinically important population health research. Examples of important areas that must be addressed to advance the field include digital inequality and possible selection bias; easy access for researchers to the appropriate data collection tools, including how best to harmonize data items; analysis methodologies for time series data; patient and public involvement and engagement methods for optimizing recruitment, retention, and public trust; and methods for providing research participants with greater control over their data. There is also a major opportunity, provided through the linkage of digital person-generated health data to routinely collected data, to support novel population health research, bringing together clinician-reported and patient-reported measures. We recognize that well-conducted studies need a wide range of diverse challenges to be skillfully addressed in unison (eg, challenges regarding epidemiology, data science and biostatistics, psychometrics, behavioral and social science, software engineering, user interface design, information governance, data management, and patient and public involvement and engagement). Consequently, progress would be accelerated by the establishment of a new interdisciplinary community where all relevant and necessary skills are brought together to allow for excellence throughout the life cycle of a research study. This will require a partnership of diverse people, methods, and technologies. If done right, the synergy of such a partnership has the potential to transform many millions of people’s lives for the better.
- Top Cited PapersOpen Access
- 9 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D977-D985
The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource
The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to >200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for >45 000 published GWAS across >5000 human traits, and >40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.
- 9 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D977-D985
Top Cited PapersOpen AccessThe NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource
The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to >200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for >45 000 published GWAS across >5000 human traits, and >40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.
- Open Access
- 13 October 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (1)
Sequencing-based genome-wide association studies reporting standards
- 13 October 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (1)
Open AccessSequencing-based genome-wide association studies reporting standards
- Top Cited Papers
- 10 March 2021
- Published by Springer Nature in Nature
- Vol. 591 (7849) , 211-219
Improving reporting standards for polygenic scores in risk prediction studies
Polygenic risk scores (PRSs), which often aggregate results from genome-wide association studies, can bridge the gap between initial discovery efforts and clinical applications for the estimation of disease risk using genetics. However, there is notable heterogeneity in the application and reporting of these risk scores, which hinders the translation of PRSs into clinical care. Here, in a collaboration between the Clinical Genome Resource (ClinGen) Complex Disease Working Group and the Polygenic Score (PGS) Catalog, we present the Polygenic Risk Score Reporting Standards (PRS-RS), in which we update the Genetic Risk Prediction Studies (GRIPS) Statement to reflect the present state of the field. Drawing on the input of experts in epidemiology, statistics, disease-specific applications, implementation and policy, this comprehensive reporting framework defines the minimal information that is needed to interpret and evaluate PRSs, especially with respect to downstream clinical applications. Items span detailed descriptions of study populations, statistical methods for the development and validation of PRSs and considerations for the potential limitations of these scores. In addition, we emphasize the need for data availability and transparency, and we encourage researchers to deposit and share PRSs through the PGS Catalog to facilitate reproducibility and comparative benchmarking. By providing these criteria in a structured format that builds on existing standards and ontologies, the use of this framework in publishing PRSs will facilitate translation into clinical care and progress towards defining best practice.
- 10 March 2021
- Published by Springer Nature in Nature
- Vol. 591 (7849) , 211-219
Top Cited PapersImproving reporting standards for polygenic scores in risk prediction studies
Polygenic risk scores (PRSs), which often aggregate results from genome-wide association studies, can bridge the gap between initial discovery efforts and clinical applications for the estimation of disease risk using genetics. However, there is notable heterogeneity in the application and reporting of these risk scores, which hinders the translation of PRSs into clinical care. Here, in a collaboration between the Clinical Genome Resource (ClinGen) Complex Disease Working Group and the Polygenic Score (PGS) Catalog, we present the Polygenic Risk Score Reporting Standards (PRS-RS), in which we update the Genetic Risk Prediction Studies (GRIPS) Statement to reflect the present state of the field. Drawing on the input of experts in epidemiology, statistics, disease-specific applications, implementation and policy, this comprehensive reporting framework defines the minimal information that is needed to interpret and evaluate PRSs, especially with respect to downstream clinical applications. Items span detailed descriptions of study populations, statistical methods for the development and validation of PRSs and considerations for the potential limitations of these scores. In addition, we emphasize the need for data availability and transparency, and we encourage researchers to deposit and share PRSs through the PGS Catalog to facilitate reproducibility and comparative benchmarking. By providing these criteria in a structured format that builds on existing standards and ontologies, the use of this framework in publishing PRSs will facilitate translation into clinical care and progress towards defining best practice.
- Top Cited Papers
- 10 March 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (4) , 420-425
The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation
We present the Polygenic Score (PGS) Catalog ( https://www.PGSCatalog.org ), an open resource of published scores (including variants, alleles and weights) and consistently curated metadata required for reproducibility and independent applications. The PGS Catalog has capabilities for user deposition, expert curation and programmatic access, thus providing the community with a platform for PGS dissemination, research and translation.
- 10 March 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (4) , 420-425
Top Cited PapersThe Polygenic Score Catalog as an open database for reproducibility and systematic evaluation
We present the Polygenic Score (PGS) Catalog ( https://www.PGSCatalog.org ), an open resource of published scores (including variants, alleles and weights) and consistently curated metadata required for reproducibility and independent applications. The PGS Catalog has capabilities for user deposition, expert curation and programmatic access, thus providing the community with a platform for PGS dissemination, research and translation.